Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $146,600.90 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,153 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $35.30, for a total value of $146,600.90. Following the sale, the insider now directly owns 161,497 shares of the company’s stock, valued at $5,700,844.10. The trade was a 2.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $40.36 on Friday. The stock has a fifty day moving average price of $30.02 and a two-hundred day moving average price of $23.12. Hims & Hers Health, Inc. has a 52-week low of $9.14 and a 52-week high of $44.43. The firm has a market capitalization of $8.82 billion, a P/E ratio of 91.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price objective for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Morgan Stanley assumed coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $25.13.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in shares of Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Hims & Hers Health by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock valued at $43,448,000 after buying an additional 129,416 shares in the last quarter. Finally, Yong Rong HK Asset Management Ltd bought a new position in Hims & Hers Health in the fourth quarter valued at about $41,104,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.